• In 2022, a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial was initiated to evaluate the safety and efficacy of HB-1 in adults diagnosed with panic disorder, either alone or with specific co-morbidities. The study enrolled male and female participants aged 18 to 60, comparing HB-1 against a placebo to determine its therapeutic potential. The trial’s completion was projected for January 2023, marking an important milestone in the development of targeted anxiety treatments.

• In 2022, HMNC Brain Health reported promising top-line outcomes from a Phase 2 proof-of-concept trial evaluating its oral prolonged-release ketamine formulation (KET01) for patients with treatment-resistant depression (TRD). The findings demonstrated encouraging therapeutic potential, reinforcing KET01’s role as an innovative approach in advanced depression management.

In this report, the Panic Disorder Market has been segmented by Treatment, Severity, Comorbidities and Geography.

Panic Disorder Market, Segmentation by Treatment

The Treatment segmentation includes Medications, Psychotherapy, Cognitive Behavioral Therapy (CBT) and Exposure & Response Prevention (ERP). Increasing emphasis on personalized treatment approaches and multimodal therapy combinations is enhancing patient outcomes. Pharmaceutical innovation and the adoption of tele-mental health solutions are reshaping the treatment landscape.

Medications

Medications remain a cornerstone of panic disorder management, primarily involving selective serotonin reuptake inhibitors (SSRIs), benzodiazepines, and serotonin-norepinephrine reuptake inhibitors (SNRIs). Increasing prescriptions of newer-generation antidepressants with favorable safety profiles and reduced side effects are fueling growth in this segment.

Psychotherapy

Psychotherapy plays a vital role in long-term management by addressing underlying psychological triggers. Demand for virtual therapy platforms and hybrid care models has surged post-pandemic, offering patients greater accessibility and engagement. Clinician training in trauma-informed and integrative therapy approaches is further strengthening this segment.

Cognitive Behavioral Therapy (CBT)

Cognitive Behavioral Therapy (CBT) is the most widely recommended non-pharmacological treatment, emphasizing thought restructuring and behavioral modification. Clinical studies show that CBT achieves response rates exceeding 70% when applied consistently. Increasing adoption of digital CBT tools and mobile applications is driving market penetration globally.

Exposure & Response Prevention (ERP)

Exposure & Response Prevention (ERP) therapy focuses on desensitizing individuals to anxiety-inducing triggers. It is often integrated with CBT for enhanced outcomes. Growing clinical validation and expansion of therapist-guided ERP programs across hospitals and specialty clinics are strengthening this segment’s role in treatment protocols.

Panic Disorder Market, Segmentation by Severity

The Severity segmentation includes Mild Panic Disorder, Moderate Panic Disorder and Severe Panic Disorder. The distribution of severity levels significantly influences treatment modality, cost, and intervention duration. Early diagnosis and preventive mental health screening are critical in mitigating progression toward severe forms.

Mild Panic Disorder

Mild panic disorder cases typically involve episodic panic attacks managed through lifestyle interventions and short-term therapy. Increasing use of digital counseling apps and mindfulness-based interventions has improved accessibility for this category of patients.

Moderate Panic Disorder

Moderate panic disorder requires combined approaches such as psychotherapy with medication. Growing clinical preference for SSRIs and CBT-based interventions supports stable remission rates. This category represents a significant share of diagnosed cases globally.

Severe Panic Disorder

Severe panic disorder involves frequent, debilitating attacks and comorbid conditions. Treatment often includes multi-drug regimens and intensive therapy. Increasing investments in psychiatric care infrastructure and expansion of inpatient and outpatient programs support this segment’s growth.

Panic Disorder Market, Segmentation by Comorbidities

The Comorbidities segmentation includes Agoraphobia, Social Anxiety Disorder, Generalized Anxiety Disorder and Depression. Comorbid mental health conditions often complicate diagnosis and treatment pathways, necessitating integrated therapeutic approaches and multidisciplinary care models. The adoption of AI-assisted diagnostic tools is improving screening accuracy across healthcare settings.

Agoraphobia

Agoraphobia is commonly linked to panic disorder, where patients avoid open or crowded spaces. Combined therapies involving CBT, ERP, and SSRIs have shown strong clinical efficacy. Increased awareness campaigns and early-stage intervention programs are reducing social stigma associated with this comorbidity.

Social Anxiety Disorder

Social Anxiety Disorder frequently co-occurs with panic symptoms, necessitating customized psychotherapeutic strategies. Growth in teletherapy adoption has enhanced accessibility to specialized anxiety management professionals.

Generalized Anxiety Disorder

Generalized Anxiety Disorder (GAD) presents overlapping symptoms with panic attacks, making diagnostic differentiation crucial. The segment benefits from pharmacological advancements in anxiolytics and serotonin modulators offering improved tolerability and response rates.

Depression

Depression is one of the most prevalent comorbidities associated with panic disorder. Combination therapy involving antidepressants, CBT, and mindfulness-based cognitive therapy shows significant improvement in symptom control and quality of life.

Panic Disorder Market, Segmentation by Geography

In this report, the Panic Disorder Market has been segmented by Geography into five regions: North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

North America

North America dominates the Panic Disorder Market due to high mental health awareness, robust healthcare infrastructure, and the strong presence of pharmaceutical and digital mental health service providers. The U.S. accounts for a significant share, supported by reimbursement frameworks for psychotherapy and telehealth services.

Europe

Europe maintains a strong position driven by mental health policy integration and increased therapy accessibility. Countries like the U.K., Germany, and France are advancing early-diagnosis programs and promoting evidence-based psychological therapies through national healthcare systems.

Asia Pacific

Asia Pacific is witnessing rapid growth due to expanding mental health awareness and rising government initiatives addressing anxiety and depression. Increasing use of mobile mental wellness platforms and the emergence of community-based counseling networks are boosting accessibility.

Middle East & Africa

Middle East & Africa show steady progress with growing recognition of mental wellness as a public health priority. Efforts toward destigmatization, coupled with investment in psychiatric care facilities and training programs, are driving gradual market expansion.

Latin America

Latin America is experiencing rising demand for affordable mental health interventions amid socioeconomic challenges. Expanding access to psychological therapies and community-based treatment programs in Brazil, Mexico, and Argentina supports regional growth.

This report provides an in depth analysis of various factors that impact the dynamics of Panic Disorders Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers

• Rising prevalence
• Increased awareness
• Technological advancements

• Integration of digital health solutions - The integration of digital health solutions represents a transformative approach to addressing the challenges associated with the diagnosis, treatment, and management of panic disorders. In an era marked by unprecedented connectivity and technological innovation, digital health solutions offer a range of tools and platforms designed to enhance access to care, empower patients, and optimize treatment outcomes. One key aspect of digital health integration in panic disorder management is the proliferation of mobile applications and online platforms designed to provide psychoeducation, self-help resources, and symptom tracking tools for individuals experiencing panic symptoms. These digital interventions offer a convenient and accessible way for patients to learn about their condition, develop coping strategies, and monitor their progress over time, thereby promoting self-management and engagement in their care.

  Digital health solutions facilitate remote monitoring and telepsychiatry services, enabling individuals with panic disorders to access timely and personalized care from the comfort of their homes. Through virtual consultations, teletherapy sessions, and remote monitoring of symptoms and vital signs, patients can receive ongoing support and guidance from mental health professionals, reducing barriers to care and improving treatment adherence. Additionally, telehealth platforms offer opportunities for collaborative care models, allowing primary care providers, psychiatrists, therapists, and other healthcare professionals to coordinate care and share information seamlessly, thereby promoting continuity of care and enhancing treatment outcomes.

Restraints

• Stigma surrounding mental health
• Disparities in access to care
• Fragmentation of mental health services

• Limited availability of specialized resources - The limited availability of specialized resources represents a significant challenge in effectively addressing panic disorders. Individuals grappling with panic disorder often require access to a range of specialized resources, including mental health professionals with expertise in anxiety disorders, specialized treatment facilities, and support services tailored to their unique needs. However, in many regions, especially in underserved areas or low-resource settings, such specialized resources may be scarce or non-existent, leading to significant barriers to diagnosis, treatment, and ongoing management of panic disorders.

  One aspect of the limited availability of specialized resources is the shortage of mental health professionals trained in the assessment and treatment of panic disorders. Psychiatrists, psychologists, and other mental health providers with expertise in anxiety disorders may be in short supply, particularly in rural areas or regions with limited access to healthcare services. As a result, individuals seeking help for panic disorders may face long wait times for appointments, limited treatment options, and challenges in finding providers who are knowledgeable about evidence-based interventions for panic disorder.

  Specialized treatment facilities dedicated to the care of individuals with panic disorders may be lacking in many regions, further exacerbating the challenges of accessing appropriate care. Panic disorder-specific treatment programs, such as intensive outpatient programs (IOPs) or residential treatment centers, offer comprehensive and multidisciplinary care tailored to the needs of individuals with severe or treatment-resistant panic disorder. However, the availability of such programs may be limited, leaving individuals with panic disorders without access to specialized care that could significantly improve their outcomes.

Opportunities

• Expansion of teletherapy and telepsychiatry
• Development of novel therapeutic interventions
• Integration of digital mental health platforms

• Increased focus on preventive mental health measures - The increased focus on preventive mental health measures represents a paradigm shift in addressing panic disorders, aiming to intervene earlier in the trajectory of mental health conditions to reduce the burden of illness and promote well-being. Traditionally, mental health care has often been reactive, focusing primarily on treating symptoms after they have manifested or escalated. However, a growing recognition of the importance of prevention has led to a reevaluation of mental health strategies, with an emphasis on identifying and addressing risk factors, promoting resilience, and fostering positive mental health from a young age.

  One key aspect of preventive mental health measures is early identification and intervention for individuals at risk of developing panic disorders. Recognizing the signs and symptoms of anxiety disorders, implementing universal screening in healthcare settings, and providing targeted interventions for individuals with subclinical anxiety symptoms can help prevent the progression to more severe forms of panic disorder. This proactive approach to early intervention can reduce the likelihood of panic disorder onset, mitigate the impact of anxiety symptoms, and improve long-term outcomes for individuals at risk.

  Preventive mental health measures encompass a range of strategies aimed at promoting mental well-being and resilience across the lifespan. Mental health promotion initiatives in schools, workplaces, and communities focus on building coping skills, fostering social connections, and enhancing emotional regulation to prevent the onset of mental health conditions, including panic disorders. By integrating mental health education into school curricula, providing workplace wellness programs, and creating supportive environments that prioritize mental well-being, preventive measures aim to create a culture of mental health awareness and support that benefits individuals and communities alike.

Panic Disorder Market is becoming increasingly competitive as pharmaceutical companies, mental health solution providers, and biotech innovators emphasize collaboration, partnerships, and targeted merger strategies. With more than 65% of market share concentrated among established players, ongoing innovation in drug development, digital therapeutics, and therapy delivery systems is fueling differentiation and long-term growth.

Market Structure and Concentration
The market reflects moderate concentration, with nearly 60% dominated by top pharmaceutical firms and mental health solution providers. Smaller companies employ niche strategies focused on novel treatment pathways and region-specific therapies. Strategic merger activity consolidates portfolios, while collaboration with research institutions and consistent innovation in treatment methods enhances competitiveness.

Brand and Channel Strategies
Around 70% of adoption is supported by multi-channel strategies including hospitals, mental health clinics, online therapy platforms, and retail pharmacies. Leading brands emphasize collaboration with healthcare providers to improve accessibility. Strategic partnerships with digital health platforms expand patient engagement, while continuous innovation in combined drug and therapy approaches supports growth.

Innovation Drivers and Technological Advancements
More than 55% of market competitiveness is shaped by technological advancements in telehealth, AI-driven diagnostics, and digital therapeutics. Companies prioritize innovation in new drug formulations and precision therapies. Strong collaboration with academic research centers accelerates development, while rising demand for accessible mental health solutions drives steady growth.

Regional Momentum and Expansion
Nearly 65% of adoption is concentrated in North America and Europe, where mental health awareness and advanced healthcare systems support expansion. Regional strategies include partnerships with healthcare networks, digital therapy providers, and universities. Collaboration in Asia-Pacific supports faster adoption, while emerging economies contribute steadily to growth through expanding mental health initiatives.

Future Outlook
The future outlook suggests that more than 70% of competitive momentum will depend on treatment innovation, advanced technological advancements, and regional expansion. Strong collaboration with healthcare providers, digital platforms, and research organizations will reinforce leadership. While dominant players sustain control, smaller firms will refine strategies to capture niche patient groups and accelerate growth.

Key players in Panic Disorders Market include:

• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• AstraZeneca plc
• Abbott Laboratories
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Pfizer Inc.
• Boehringer Ingelheim International GmbH
• Recordati S.p.A.
• Neurocrine Biosciences, Inc.
• Sanofi S.A.
• Janssen (Johnson & Johnson)
• Addex Pharmaceuticals

In this report, the profile of each market player provides following information:

• Market Share Analysis
• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis